Publications by authors named "Mark Lynch"

Claim this Profile
L
Low-Cost Hyperelastic Fuller-Dome-Structured Nanocellulose Aerogels by Dual Templates for Personal Thermal Management.
Guang Wang, Jiabing Feng, Zhezhe Zhou, Zheng Liu, Jianpeng Wu, Mark Lynch

Adv Mater· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of eccDNA in Extracellular Vesicles Derived from Human Dermal Fibroblasts Through Nanopore Sequencing.
Bianca Simonassi-Paiva, Julia Alves Luz, Julia Hellena Ribeiro, Juliano Coelho da Silveira, Camila Azzolin de Souza, Mark Lynch

Int J Mol Sci· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Laparoscopic common bile duct exploration and retrieval of endoscopic lithotripsy basket after mechanical failure.
Lawrence Nip, Mark Lynch, Zinu Philipose, Serena Ceraldi

J Minim Access Surg· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analysis of SARS-CoV-2 antibody seroprevalence in Northern Ireland during 2020-2021.
Michelle K Greene, Peter Smyth, Andrew English, Joseph McLaughlin, Magda Bucholc, Mark Lynch

Heliyon· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synergy Assessment of Four Antimicrobial Bioactive Compounds for the Combinational Treatment of Bacterial Pathogens.
Kevin Masterson, Ian Major, Mark Lynch, Neil Rowan

Biomedicines· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Microfluidic live tracking and transcriptomics of cancer-immune cell doublets link intercellular proximity and gene regulation.
Bianca C T Flores, Smriti Chawla, Ning Ma, Chad Sanada, Praveen Kumar Kujur, Mark Lynch

Commun Biol· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of a low-temperature extrusion process for production of GRAS bioactive-polymer loaded compounds for targeting antimicrobial-resistant (AMR) bacteria.
Kevin Masterson, Elaine Meade, Mary Garvey, Mark Lynch, Ian Major

Sci Total Environ· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Advances in Non-Animal Testing Approaches towards Accelerated Clinical Translation of Novel Nanotheranostic Therapeutics for Central Nervous System Disorders.
Mark J Lynch, Oliviero L Gobbo

Nanomaterials (Basel)· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chemotherapy induces canalization of cell state in childhood B-cell precursor acute lymphoblastic leukemia.
Virginia A Turati, José Afonso Guerra-Assunção, Nicola E Potter, Rajeev Gupta, Simone Ecker, Mark Lynch

Nat Cancer· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Î
β-Glucan extracts from the same edible shiitake mushroom Lentinus edodes produce differential in-vitro immunomodulatory and pulmonary cytoprotective effects - Implications for coronavirus disease (COVID-19) immunotherapies.
Emma J Murphy, Claire Masterson, Emanuele Rezoagli, Daniel O'Toole, Ian Major, Mark Lynch

Sci Total Environ· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Role of Gastrografin in Patients With Small Bowel Obstruction.
Ibrahim Almafreji, Ugochukwu Chinaka, Amir Hussain, Mark Lynch, Richard Cottrell

Cureus· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use.
Robert L Ferris, Lisa Licitra, Jerome Fayette, Caroline Even, George Blumenschein, Mark Lynch

Clin Cancer Res· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial.
Robert Haddad, Fernando Concha-Benavente, George Blumenschein, Jerome Fayette, Joel Guigay, Mark Lynch

Cancer· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrated Fluidic Circuits for Single-Cell Omics and Multi-omics Applications.
Mark Lynch, Naveen Ramalingam

Adv Exp Med Biol· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Miniaturised interaction proteomics on a microfluidic platform with ultra-low input requirements.
Cristina Furlan, René A M Dirks, Peter C Thomas, Robert C Jones, Jing Wang, Mark Lynch

Nat Commun· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer.
Maura L Gillison, George Blumenschein, Jerome Fayette, Joel Guigay, A Dimitrios Colevas, Mark Lynch

Oncologist· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study.
Sundar Jagannath, Jacob Laubach, Ellice Wong, Keith Stockerl-Goldstein, Cara Rosenbaum, Mark Lynch

Br J Haematol· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hemolysis Rates in Whole Blood Samples for Blood Gas/Electrolyte Analysis by Point-of-Care Testing.
Amanda Wilson, Maranna Sweeney, P L Mark Lynch, Maurice J O'Kane

J Appl Lab Med· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression.
Robert L Ferris, George Blumenschein, Jerome Fayette, Joel Guigay, A Dimitrios Colevas, Mark Lynch

Oral Oncol· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predicting Nucleation of Isonicotinamide from the Solvent-Solute Interactions of Isonicotinamide in Common Organic Solvents.
Mark B Lynch, Simon E Lawrence, Michael Nolan

J Phys Chem A· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
VKORC1 sequence variants associated with resistance to anticoagulant rodenticides in Irish populations of Rattus norvegicus and Mus musculus domesticus.
Jean Mooney, Mark R Lynch, Colin V Prescott, Tracy Clegg, Michael Loughlin

Sci Rep· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, open-label, Phase III clinical trial of nivolumab vs. therapy of investigator's choice in recurrent squamous cell carcinoma of the head and neck: A subanalysis of Asian patients versus the global population in checkmate 141.
Naomi Kiyota, Yasuhisa Hasegawa, Shunji Takahashi, Tomoya Yokota, Chia-Jui Yen, Mark Lynch

Oral Oncol· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.
Kevin J Harrington, Robert L Ferris, George Blumenschein, A Dimitrios Colevas, Jérôme Fayette, Mark Lynch

Lancet Oncol· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum to: Surface layer proteins from virulent Clostridium difficile ribotypes exhibit signatures of positive selection with consequences for innate immune response.
Mark Lynch, Thomas A Walsh, Izabela Marszalowska, Andrew E Webb, Micheál Mac Aogáin

BMC Evol Biol· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Surface layer proteins from virulent Clostridium difficile ribotypes exhibit signatures of positive selection with consequences for innate immune response.
Mark Lynch, Thomas A Walsh, Izabela Marszalowska, Andrew E Webb, Micheál Mac Aogain

BMC Evol Biol· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis